Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) and Genelux (NASDAQ:GNLX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.
Insider and Institutional Ownership
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Foghorn Therapeutics and Genelux, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Foghorn Therapeutics | 1 | 5 | 4 | 0 | 2.30 |
| Genelux | 1 | 0 | 3 | 1 | 2.80 |
Profitability
This table compares Foghorn Therapeutics and Genelux’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
| Genelux | N/A | -205.85% | -138.79% |
Risk and Volatility
Foghorn Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Genelux has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.
Earnings & Valuation
This table compares Foghorn Therapeutics and Genelux”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Foghorn Therapeutics | $30.91 million | 3.84 | -$74.28 million | ($0.98) | -2.04 |
| Genelux | $10,000.00 | 11,581.44 | -$32.15 million | ($0.86) | -2.98 |
Genelux has lower revenue, but higher earnings than Foghorn Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Foghorn Therapeutics beats Genelux on 8 of the 15 factors compared between the two stocks.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
